Premium
Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects
Author(s) -
Neelakantan Pratap,
Rezvani Katayoun,
May Philippa,
Gerrard Gareth,
Marco Bua,
Paliompeis Christos,
Reid Alistair,
Goldman John,
Marin David,
Milojkovic Dragana
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12648
Subject(s) - nilotinib , dasatinib , bosutinib , medicine , side effect (computer science) , imatinib , tyrosine kinase inhibitor , imatinib mesylate , tyrosine kinase , drug holiday , myeloid leukemia , oncology , immunology , cancer , receptor , human immunodeficiency virus (hiv) , computer science , programming language
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom